RxDoctor Payments Data

Lewis Rose, MD

Hematology & Oncology · Philadelphia, PANPI 1407923113

Payments from drug & device makers

$1,438in general payments, 2019–2025

Across 57 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$223
  • Daiichi Sankyo Inc.$180
  • Astellas Pharma US Inc$175
  • E.r. Squibb & Sons, L.L.C.$164
  • Array Biopharma Inc$127
  • Eisai Inc.$123
  • plus $448 from 8 others

What the payments were for

  • Food & beverage$1,27689%
  • Education$16211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,438 in reported general payments places this provider in the 35th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$67,929
Medicare patients
144
Services billed
458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib30$532,547
EmpaveliPegcetacoplan13$492,183
Lenalidomide30$360,960
StivargaRegorafenib13$223,306
CalquenceAcalabrutinib Maleate14$207,601
VerzenioAbemaciclib18$202,316
KisqaliRibociclib Succinate12$178,360
VenclextaVenetoclax17$102,510
EliquisApixaban87$84,509
Abiraterone Acetate42$25,370
Tenofovir Disoproxil Fumarate16$6,020
Exemestane27$2,558
Anastrozole106$2,160
ValacyclovirValacyclovir Hcl32$1,117
Pantoprazole Sodium16$1,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$223$207,60114 claims
NovartisKisqali$84$178,36012 claims
PfizerEliquis$36$84,50987 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 682 hematology & oncology providers in Pennsylvania.

Other hematology & oncology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →